Kyowa Hakko Kirin

Global Pharma, Biotech & Diagnostics Co-promotion and Co-marketing Partnering Terms and Agreements Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022

The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive access to records for over 400 co-promotion and co-marketing deals.
  • This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
  • Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2015 to 2022.

Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022: An Understanding and Analysis of How and Why Companies Enter Distribution Deals - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022

The "Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015 to 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015 to 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides a detailed understanding and analysis of how and why companies enter distribution deals.
  • There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.

Global Pharma, Biotech and Diagnostics Manufacturing and Supply Partnering Deal Terms and Agreements Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022

The "Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive access to available records for over 2,700 maufacturing and supply deals, including contract documents where available.
  • The report provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.
  • Manufacturing and supply agreements provide a popular method of maximizing the value of a product launched into a market.

MEI Pharma Announces Adjournment of Annual Meeting of Stockholders

Retrieved on: 
Tuesday, December 6, 2022

MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time.

Key Points: 
  • MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time.
  • MEI Pharma stockholders and proxyholders will be able to attend and participate in the reconvened annual meeting online, be deemed to be present in person and vote their shares electronically, and submit questions prior to and during the reconvened annual meeting by visiting https://meetnow.global/MTGT7UU and entering their control number found on the proxy card they previously received for the annual meeting.
  • Because this information was released so soon before the annual meeting, MEIs management and board of directors decided to propose an adjournment of the annual meeting to give MEIs stockholders a chance to consider this information.
  • No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting.

MEI Pharma Initiates Strategic Realignment

Retrieved on: 
Monday, December 5, 2022

As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344.

Key Points: 
  • As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344.
  • The company further announced that it has engaged Torreya Partners as financial advisor to help explore additional strategic opportunities.
  • We intend to continue development of our earlier-stage clinical assets, streamline MEIs operations towards these efforts, and consider additional strategic opportunities, said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma.
  • MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company focused on developing potential new therapies for cancer.

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

Retrieved on: 
Monday, December 5, 2022

Based on the most recent guidance received from the FDA at a late November meeting, we have jointly decided with Kyowa Kirin to discontinue development of zandelisib outside of Japan.

Key Points: 
  • Based on the most recent guidance received from the FDA at a late November meeting, we have jointly decided with Kyowa Kirin to discontinue development of zandelisib outside of Japan.
  • In late November 2022, MEI Pharma and Kyowa Kirin met with the FDA in a follow-up meeting to the March 2022 end of Phase 2 meeting.
  • In April 2020, MEI and Kyowa Kirin entered a global license, development, and commercialization agreement to further develop and commercialize zandelisib.
  • MEI and Kyowa Kirin were to co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales.

Another Award for Synaffix: 'Business Development Team of Year' at the Scrip Awards

Retrieved on: 
Tuesday, December 13, 2022

The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.

Key Points: 
  • The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.
  • The BD Team has been instrumental in the signing of six licensing deals during the award qualifying period with deal values around $500 million to $1 billion.
  • These include agreements with Mersana ($1b), Genmab ($415m), Macrogenics ($586m), Kyowa Kirin (value not disclosed) and Emergence Therapeutics ($360m).
  • toxSYN is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E and SYNeamicin G, among other linker-payloads.

Another Award for Synaffix: 'Business Development Team of Year' at the Scrip Awards

Retrieved on: 
Tuesday, December 13, 2022

The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.

Key Points: 
  • The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.
  • The BD Team has been instrumental in the signing of six licensing deals during the award qualifying period with deal values around $500 million to $1 billion.
  • These include agreements with Mersana ($1b), Genmab ($415m), Macrogenics ($586m), Kyowa Kirin (value not disclosed) and Emergence Therapeutics ($360m).
  • toxSYN is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E and SYNeamicin G, among other linker-payloads.

Global Pharma, Biotech and Diagnostics Option and Evaluation Partnership Terms and Agreements Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022

The "Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive access to available records for over 1,400 option and evaluation deals, including contract documents where available.
  • The report provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.
  • Insight into the terms included in a option and evaluation agreement, together with real world clause examples
    Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 includes:
    Available deals are listed by:

Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio

Retrieved on: 
Thursday, November 24, 2022

Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grnenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

Key Points: 
  • Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grnenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.
  • The Joint Venture Collaboration is subject to obtaining customary approvals and clearances, including anti-trust and works councils as legally required.
  • Grnenthal will make an additional payment upon purchase of the remaining share and the intellectual property (IP) of the portfolio.
  • Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
    Grnenthal is a global leader in pain management and related diseases.